MedTrace Logo

Houston "Breathe Easy" Healthy Homes-Based Model for Multifamily Rental Communities

NCT05345080 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2022-06-06

No results posted yet for this study

Summary

The primary purpose of this pragmatic randomized clinical trial is to examine whether the addition of a phone-based multicomponent environmental intervention customized for Houston public housing residents with asthma will result in statistically significant improvements in key measures of health, quality of life, and resilience.

Conditions

  • Asthma
  • Respiratory Tract Disease
  • Lung Diseases
  • Sinusitis, Chronic

Interventions

BEHAVIORAL

Exposure-Reduction Intervention

The customized exposure-reduction intervention includes a phone-based telehealth visit, collection of self-report information from detailed health and exposure questionnaires, asthma education, assessment for allergies (optional), and a customized asthma self-management and exposure-reduction plan developed using motivational interviewing techniques, support, and exposure-reduction supplies.

Sponsors & Collaborators

  • Harris County Hospital District

    collaborator OTHER_GOV

  • The University of Texas Health Science Center, Houston

    collaborator OTHER

  • Oregon State University

    collaborator OTHER

  • Baylor College of Medicine

    lead OTHER

Principal Investigators

  • Winifred J Hamilton, PhD, SM · Baylor College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-27
Primary Completion
2022-06-30
Completion
2022-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05345080 on ClinicalTrials.gov